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To facilitate a more efficient radiation and chemotherapy of mammary tumours, synthetic enhancer elements responsive to hypoxia and
ionizing radiation were coupled to the mammary-specific minimal promoter of the murine whey acidic protein (WAP) encoding gene. The
modified WAP promoter was introduced into a retroviral promoter conversion (ProCon) vector. Expression of a transduced reporter gene in
response to hypoxia and radiation was analysed in stably infected mammary cancer cell lines and an up to 9-fold increase in gene expression
demonstrated in comparison to the respective basic vector. Expression analyses in vitro, moreover, demonstrated a widely preserved mammary
cell-specific promoter activity. For in vivo analyses, xenograft tumours consisting of infected human mammary adenocarcinoma cells were
established in SCID/beige mice. Immunohistochemical analyses demonstrated a hypoxia-specific, markedly increased WAP promoter-driven
expression in these tumours. Thus, this retroviral vector will facilitate a targeted gene therapeutic approach exploiting the unique environmental
condition in solid tumours.
© 2006 Elsevier Inc. All rights reserved.Keywords: CArG element; Hypoxia responsive element; Promoter conversion; Retroviral vector; Breast cell-specific expression targeting; Breast cancer xenografts;
Mouse modelIntroduction
Hypoxia is one of the critical factors which prevent success-
ful cancer therapy. The presence of hypoxic regions in
tumours adversely affects the locoregional control and/or
disease-free survival after primary radiotherapy, chemotherapy
and surgery (De Schutter et al., 2005; Fyles et al., 1998, 2002;
Hockel et al., 1996; Nordsmark et al., 2001; Zhou et al.,
2005). Hypoxia is a special feature of solid tumours which is
mainly due to their insufficient blood supply caused by a⁎ Corresponding author. Research Institute of Virology and Biomedicine,
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doi:10.1016/j.virol.2005.12.038highly irregular, tortuous, and elongated vasculature with
blind ends, incomplete endothelial linings and irregular blood
flow (Kimura et al., 1996; Vaupel et al., 1991). Furthermore,
cancer patients often suffer from anaemia which in addition
leads to a generally reduced oxygen supply (Blohmer et al.,
2005; Vaupel and Mayer, 2005). These factors contribute to
the emergence of variable areas of transient and chronic
hypoxia in distinct tumour regions. Low oxygenation of
tumour cells, however, can accelerate malignant progression
and metastasis and as a consequence contribute to a poor
prognosis (Brizel et al., 1996; Dales et al., 2005; To et al.,
2005). In this respect, it was shown that hypoxia leads to an
upregulation of expression of anti-apoptotic factors such as
Bcl-2 (Shimizu et al., 1995), whereas expression of cell
adhesion molecules such as integrins is downregulated (Hasan
122 K. Lipnik et al. / Virology 349 (2006) 121–133et al., 1998). Furthermore, it was reported that expression of
the urokinase-type plasminogen activator receptor (Rofstad et
al., 2002) or the autocrine motility factor (Niizeki et al., 2002)
is upregulated under hypoxic conditions. All these events
facilitate tumour cell detachment, migration and invasion.
With respect to radio- and chemotherapy of tumours, it has
been shown that low oxygenated cells are three times more
resistant to radiation-induced cell death than normoxic cells
(Harrison and Blackwell, 2004). On the basis of this
information, different strategies are currently developed to
specifically target hypoxic tumour regions.
In order to achieve hypoxia-specific expression, hypoxia
responsive elements (HREs) located within enhancer regions of
various hypoxia-regulated genes such as those encoding
erythropoietin (Epo), phosphogycerate kinase 1 (PGK1),
vascular endothelial growth factor (VEGF), or lactate dehydro-
genase A (LDH A) have been used (Greco et al., 2003). These
HREs are cis acting sequences containing the core motif 5′-(A/
G)CGT(G/C)(G/C)-3′ and several transcription factor binding
sites, one of which is essential for hypoxic activation by binding
the hypoxia-inducible factor (HIF) 1 (Semenza and Wang,
1992). Linking HREs to the constitutively active minimal CMV
promoter has been shown to confer hypoxia responsiveness to
gene expression (Greco et al., 2002; Marples et al., 2000).
Similarly, the promoter of the early growth response (Egr)-1
gene has been used successfully to facilitate expression of a
transgene following radiation treatment (Hallahan et al., 1995).
Based on this, synthetic promoters, bearing the consensus
sequence CC(A/T)6GG which is known as CArG element
(Datta et al., 1992), were shown to specifically mediate
activation of gene expression in response to radiotherapy in
vitro (Greco et al., 2002). The successful combination of both
elements, five copies of HREs coupled to nine copies of CArG
elements (Epo/E9), in an approach addressing the problem of
hypoxia in radiotherapy of solid tumours was published
previously (Greco et al., 2002).
In order to further exploit this system for cancer gene
therapy, a retroviral vector-based gene delivery system was
adapted to enable a mammary tissue-targeted, hypoxia- and
radiation-inducible expression of transferred genes. We have
previously reported a highly effective vector system derived
from murine leukaemia virus (MLV) which facilitates targeted
expression of transduced genes by promoter conversion
(Hlavaty et al., 2004). In this system, transgene expression
in virus packaging cells is driven from the MLV promoter
within the 5′ long terminal repeat (LTR). After infection and
reverse transcription, the MLV promoter is replaced by the
heterologous tissue-specific promoter which is copied from
the 3′ LTR to the 5′ LTR (Mrochen et al., 1997; Saller et al.,
1998). To obtain tissue-specific expression in this study, a
470-bp fragment of the murine whey acidic protein (WAP)
promoter was used, which had been shown recently in a
transgenic mouse model to target the expression of transferred
genes exclusively to the mammary gland (Lipnik et al.,
2005). Since retroviral vectors stably integrate into the
genome of infected cells, first of all, the functionality of
the combined Epo/E9 enhancer element in stably transfectedmammary cancer cells was tested. Transient and chronic
hypoxia as well as a fractionated X-ray exposure resulted in a
5- to 50-fold increase of EGFP expression dependent on the
respective cell line. Based on these results, a promoter
conversion vector was generated carrying an EGFP gene
under the control of a hybrid promoter consisting of the Epo/
E9 enhancer element directly linked to the WAP promoter
sequence. By means of in vitro infection experiments, we
could demonstrate not only inducibility of EGFP expression
by hypoxia and radiation but also a preserved cell-type
specificity of the modified WAP promoter. Finally, in vivo
function analyses with stably infected human breast cancer
cell xenografts clearly demonstrated enhanced EGFP expres-
sion in hypoxic tumour regions.
Results
The Epo/E9 element facilitates long term expression of EGFP
in response to hypoxia and radiation
Primary experiments were designed to determine whether
the combined synthetic hypoxia and radiation responsive
enhancer element is functional in well differentiated human
breast cancer cell lines, i.e., MCF7 and T47D, as well as in a
cell line derived from a breast cancer metastasis, i.e., MDA-
MB435S. In addition, the long-term expression response in
these cells after stimulation was investigated. For this
purpose, MCF7, T47D cells and MDA-MB435S cells were
stably transfected with the expression vector pEpoE9GFP
(Greco et al., 2002), and EGFP expression was determined by
fluorescence-activated cell sorting (FACS).
For induction of expression by transient hypoxia, cells were
incubated with CoCl2 for 4 h, which mimics hypoxia, including
the production of reactive oxygen species (Minchenko et al.,
2005; Vengellur et al., 2005). A concentration of 2–4 μM was
already sufficient to provoke hypoxic conditions as demonstrat-
ed by immunocytochemical staining of exposed T47D cells
(data not shown). To investigate the duration of enhanced
expression activity after 4 h of CoCl2 treatment, cells were
further maintained in normal medium at normoxic conditions for
24 h to 144 h. Each of the investigated cell lines showed an
individual reaction with expression maxima at different time
points varying between 72 h and 120 h (Fig. 1A). T47D cells
showed a steady increase of EGFP expression within 144 h of re-
oxygenation. In comparison to non-treated cells, EGFP
expression levels in CoCl2-treated human breast cancer cells
increased 22- to 57-fold.
Two different methods were chosen to simulate chronic
hypoxia in stably transfected breast cancer cells. Firstly, cells
were incubated with individual amounts of CoCl2 (0.1, 0.3 or
0.5 μM; see Materials and methods) for 12 h–96 h (Fig. 1B).
Thereby, about a 6-fold increase in EGFP expression levels was
achieved with T47D and MCF7 cells, whereas transfected
MDA-MB435S cells revealed a slight increase (2-fold) after 96
h. Secondly, cells were incubated in a hypoxic chamber in the
presence of an oxygen reduced atmosphere for a maximum of
96 h. EGFP expression was determined by FACS analysis at
Fig. 1. (A–D): Effects of hypoxia and X-ray exposure on EGFP expression
levels in human breast cancer cells stably transfected with pEpoE9GFP. EGFP
expression levels were determined as the total mean fluorescence intensity
(MFI) of EGFP expressing and non-expressing cells and are depicted as fold
increase in relation to non-treated cells. Indicated are the mean values including
standard deviations of three independent experiments. (A) Transient hypoxia
induced by CoCl2. Stably transfected T47D, MCF7 and MDA-MB435S cells
were incubated with 2–4 μM CoCl2 for 4 h and thereafter cultivated in the
respective cell-specific medium under normoxic conditions for the indicated
time spans. After re-oxygenation EGFP expression was determined by FACS.
(B) Chronic hypoxia induced by CoCl2. Cells were incubated for the indicated
time spans with 0.1 to 0.5 μM CoCl2 and subsequently analysed by FACS. (C)
Cells were incubated for the indicated time spans in a hypoxic chamber and
subsequently analysed by FACS. (D) Stably transfected T47D, MCF7 and
MDA-MB435S cells were exposed up to five times to X-ray radiation (2.6 Gy
each) and subsequently analysed by FACS.
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5-fold increase in EGFP expression levels was achieved
depending on the respective cell line. Again, MDA-MB435S
cells were barely inducible as demonstrated by an only 1.3-fold
increase in expression levels after 96 h.
Since the Epo/E9 enhancer, besides the HRE, also contains
9 copies of radiation response elements, the stably transfected
cell lines were tested for their reaction to X-ray exposure with
respect to EGFP expression. In order to simulate a clinical
radiation scheme (Truong et al., 2004; Whelan et al., 2002)
cells were irradiated up to five times every 24 h with a dose of
2.6 Gy. 48 h after the last irradiation cells were harvested and
analysed by FACS (Fig. 1D). Expression activity increased
with repeated radiation doses. MCF7 cells showed a 4.5-fold
increase in EGFP expression after five consecutive irradia-
tions. MDA-MB435S cells revealed a 3.6-fold higher total
MFI compared to non-irradiated cells. T47D cells showed a
2.4-fold increase in EGFP expression levels after four cycles
of X-ray exposure.
Generation of a radiation- and hypoxia-inducible breast
cell-specific retroviral vector
Since the hypoxia- and radiation-inducible enhancer ele-
ments had been shown to be active in stably transfected human
breast cancer cells, they subsequently were inserted into a
retroviral promoter conversion (ProCon) vector carrying the
mammary tissue-specific murine WAP promoter (Fig. 2B). To
achieve this, the Epo/E9 enhancer element was amplified by
PCR from pEpoE9GFP (Fig. 2A) and inserted into the plasmid
pPCEW (Fig. 2B) 5′ of the WAP promoter within the 3′ LTR.
The generated ProCon vector pPCE-EpoE9W (Fig. 2C) as well
as the basic vector pPCEW (Fig. 2B) were stably transfected
into 2GP19Talf amphotropic retroviral packaging cells (Pam-
balk et al., 2002). Stably transfected cell populations as well as
single cell clones were isolated and virus titres were determined
by real-time reverse transcriptase (RT)-PCR of viral RNA
extracted from cell culture supernatant. Virus titres of 5 × 106/
ml for cell populations and 1 × 108/ml for isolated virus
producing cell clones were obtained. No significant differences
in virus titres were observed when pPCE-EpoE9W transfected
packaging cells were compared to those transfected with the
basic vector pPCEW. Virus containing supernatant from high
titre producing cell clones was then used to infect T47D, MCF7,
and MDA-MB435S cells. Stably transduced cell populations
and single cell clones were selected and further investigated for
their response to hypoxia and radiation.
Stably pPCE-EpoE9W-transduced breast cancer cells respond
to hypoxia and radiation
In order to characterise the obtained stably transduced cell
clones and populations they were analysed for hypoxia and
radiation responsiveness by exposure to hypoxic conditions and
X-ray irradiation as established before. As a control, cell
populations and clones stably transduced with the basic vector
PCEW lacking the Epo/E9 element were stimulated in the same
Fig. 2. Expression constructs and retroviral vectors. (A) The expression plasmid pEpoE9GFP carries five copies of a HRE derived from the erythropoietin gene (Epo)
and nine copies of a CArG element of the Egr I gene (E9) which are coupled to a minimal CMV promoter (CMV). This promoter drives the expression of the marker
gene EGFP which is followed by a SV40 polyadenylation signal. It contains a SV40 promoter/neomycin resistance gene (SV40 neo) selection cassette and an
ampicillin resistance gene (Amp) as a bacterial selection marker. (B) The plasmid pPCEW contains a retroviral ProCon vector which is based on MLV. A CMV
enhancer was inserted upstream of the 5′ long terminal repeat (LTR) within the plasmid backbone. TheMLV promoter within the U3 region of the 3′ LTRwas replaced
by a 470-bp fragment of the murineWAP promoter. The vector contains an elongated attachment site and an additional polyadenylation signal downstream of theWAP
promoter. EGFP was included as a reporter gene followed by a SV40-neo selection cassette. (C) The plasmid pPCE-EpoE9W contains in addition to theWAP promoter
in the 3′ LTR the Epo/E9 enhancer element inserted directly upstream of the respective promoter sequence.
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increase in EGFP expression levels was observed when PCE-
EpoE9W-transduced breast cancer cells were exposed either to
transient or chronic hypoxia. Interestingly, cells stably infected
with PCEW in comparison to non-treated cells in some cases
showed a decrease in EGFP expression levels when exposed to
hypoxic conditions (Table 1). PCEW-transduced MCF7 cells
exposed to transient hypoxia, however, revealed an about 2-fold
increase in EGFP expression.
The radiation responsiveness of the newly generated vector
was investigated by fractionated irradiation of stably trans-
duced cells. Cells were irradiated five times with 2.6 Gy and,
subsequently analysed by FACS. On average, dependent on
the respective cell line tested, a 2-fold to 5-fold increase in
expression levels was obtained (Table 1). In contrast to the
results obtained with hypoxic conditions, X-ray exposure
caused a marked increase of EGFP expression levels
especially in PCEW-transduced T47D cells when compared
to non-treated cells.
The hypoxia responsiveness of the EpoE9-WAP promoter is
mainly restricted to breast cancer cells
In order to determine if the modified WAP promoter is still
able to confer breast cell-specific gene expression in transduced
cells, four different human mammary cancer cell lines (Hs578T,
MDA-MB435S, T47D, MCF7) as well as five human non-
mammary cancer cell lines including microvascular endothelial
cells (HMEC), embryonic kidney cells (HEK293), primary
normal human fibroblasts (huFi), a pancreatic cancer cell line
(Panc1) and a cervix carcinoma cell line (HeLa) were infected
with the respective retroviral vectors PCE-EpoE9W and PCEW
(Fig. 3). Subsequently, EGFP expression in response to hypoxia
was analysed and results obtained in non-mammary cancer cells
compared to those obtained in mammary cancer cells. Non-
selected populations of mammary cancer cells transientlyinfected with PCE-EpoE9W (Fig. 3A) show a clear increase of
EGFP expression levels after cultivation in hypoxic conditions
whereas the response to hypoxia in non-breast cancer cells
besides endothelial cells (HMEC) is only modest (Fig. 3A). Cell
populations which were transiently infected with the pPCEW
vector, on average did not show a significant response with
respect to expression activity (Fig. 3B). However, transduced
HMEC again revealed an enhanced EGFP expression when
treated with 0.5 μM CoCl2.
In order to exclude an influence of cell line infectability or
different viral titres, stably infected cell populations were
generated. Stably transduced cells were cultured in a hypoxic
chamber for 96 h and subsequently analysed by FACS.
Comparable to the transiently infected cells mainly PCE-
EpoE9W stably transduced breast cancer cell lines such as
Hs578T, T47D and MDA-MB435S showed an increase in
EGFP expression levels in response to hypoxia (Fig. 4A). Only
a minimal effect was achieved with MCF7 cells which also did
not react to hypoxic chamber-mediated hypoxia in the previous
experiment (Fig. 3A, black bar). In comparison, EGFP
expression levels in stably PCEW-infected cells on average
rather decreased than increased (Fig. 4B). In summary,
normalised to the basic WAP promoter ProCon vector PCEW
the modified PCE-EpoE9W vector facilitated a 4.6-fold to 9.3-
fold enhancement of EGFP expression in hypoxic breast cancer
cell lines compared to a 1.6-fold to 4.3-fold stimulation of
expression in hypoxic non-breast cancer cells (Fig. 4C).
Stably transduced mammary cancer cell xenografts show
enhanced marker gene expression in hypoxic tumour regions
Following the in vitro analyses, inducibility of the modified
WAP-promoter by hypoxia was also tested in vivo, since it is
known that the maximum activity of the WAP promoter is
achieved in a three-dimensional system (Lin et al., 1995). For
this purpose, cell clones and populations of MCF7, T47D and
Table 1
Fold increase of EGFP expression in MDA-MB435S, T47D and MCF7 cells
stably infected with PCEW or PCE-EpoE9W in response to hypoxia or X-ray
exposure a
Transient
hypoxia
CoCl2
Chronic
hypoxia
CoCl2
Chronic hypoxia
hypoxic chamber
Fractionated
irradiation
MDA-PCE-
EpoE9W
pop
2.6 ± 0.1 2.7 ± 1.7 2.1 ± 0.2 1.7 ± 0.08
MDA-PCE-
EpoE9W
cl 5
3.0 ± 1.1 1.6 ± 0.4 1.9 ± 0.2 2.6 ± 1.0
MDA-
PCEW
pop
1.0 ± 0.1 0.8 ± 0.08⁎ 0.6 ± 0.08⁎ 0.8 ± 0.02
MDA-
PCEW
cl 2
1.4 ± 0.8 0.7 ± 0.01⁎ 0.7 ± 0.05 1.3 ± 0.6
T47D-PCE-
EpoE9W
pop
3.2 ± 0.01 4.1 ± 0.07 3.1 ± 0.3 5.0 ± 0.1
T47D-PCE-
EpoE9W
cl 3
3.9 ± 2.4 4.5 ± 1.5 2.3 ± 0.3 5.4 ± 0.6
T47D-
PCEW
pop
0.7 ± 0.1⁎ 1.1 ± 0.09 0.7 ± 0.1⁎ 6.4 ± 0.2
T47D-
PCEW
cl 4
0.7 ± 0.3 1.4 ± 0.4 0.8 ± 0.07 3.1 ± 0.5
MCF7-
PCE-
EpoE9W
pop
2.3 ± 0.4 2.7 ± 0.4 1.6 ± 0.2 2.2 ± 0.2
MCF7-
PCE-
EpoE9W
cl 11
2.0 ± 0.5 3.0 ± 0.1 1.1 ± 0.09 2.3 ± 0.3
MCF7-
PCEW
pop
2.2 ± 1.0 0.9 ± 0.1 0.6 ± 0.07⁎ 1.8 ± 0.07
MCF7-
PCEW
cl 13
1.7 ± 0.5 1.0 ± 0.08 0.6 ± 0.1 1.9 ± 0.3
a The numbers represent mean values of three independent experiments
including standard deviations.
⁎ Significant decrease as determined by an unpaired t test.
Fig. 3. Breast cell-specific, hypoxia-mediated induction of EGFP expression in
transiently transduced human cell lines. Four different breast cancer cell lines
(Hs578T, T47D, MDA, MCF7) and various non-breast cancer cell lines (HeLa,
293, PancI) as well as normal human fibroblasts (huFi) and a microvascular
endothelial cell line (HMEC) were infected with PCE-EpoE9W (A) or with the
basic vector PCEW (B). 72 h after infection cells were treated either with 0.1 or
0.5 μM CoCl2 or cultured in an oxygen-reduced atmosphere to induce hypoxic
conditions. After 96 h of treatment cells were analysed by FACS and compared
to cells cultured under normoxic conditions.
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PCEW were implanted into the mammary fat pad of immune
incompetent SCID/beige mice to allow formation of xenograft
tumours. Five weeks after implantation of the tumour cells,
mice were injected intraperitoneally with a single dose of
pimonidazole hydrochloride to facilitate detection of hypoxic
tumour regions (Cowen et al., 2004). Thereafter mice were
sacrificed, tumours excised and prepared for immunohisto-
chemical analyses. Consecutive tissue sections were stained
either for detection of EGFP or hypoxic cells indicated by the
presence of pimonidazole-protein adducts (Azuma et al., 1997).
A high level EGFP expression was detected in xenografts
derived from PCE-EpoE9W-transduced tumour cells mainly inhypoxic regions in the periphery of blood vessels (Figs. 5E, F)
and in close vicinity to necrotic areas (Figs. 5G, H). In contrast,
PCEW-transduced tumour cells showed maximal EGFP
expression when located next to vessels and expression activity
decreased adjacent to necrotic areas (Figs. 5A–D). Co-
localisation of hypoxic and EGFP-expressing cells by means
of fluorescence immunohistochemistry clearly demonstrated an
enhanced expression activity of PCE-EpoE9W in hypoxic
tumour cells (Figs. 6B, D). In tumour xenografts derived from
cells infected with the basic vector PCEW, however, EGFP
expression in hypoxic cells was hardly detected (Figs. 6A, C).
In order to quantify the effect of the Epo/E9 enhancer
elements on WAP promoter-driven EGFP expression in vivo,
FACS analysis of single cell suspensions obtained from six
different tumour xenografts originating from a PCEW-, or
respectively PCE-EpoE9W-infected T47D cell clone were
performed. Both cell clones revealed comparable EGFP
expression levels in vitro with more than 90% EGFP expressing
cells and similar MFIs. FACS analysis of tumour tissue derived
from PCEW-infected cells in contrast demonstrated that on
average only 3.6% of the analysed cells expressed EGFP (Fig.
7, upper left panel). In comparison, tumours derived from PCE-
EpoE9W-transduced cells on average revealed 53.1% green
cells (Fig. 7, lower left panel). These results were confirmed by
immunohistochemistry (Fig. 7, right panels). EGFP expression
in tumour sections derived from PCEW-transduced T47D cells
Fig. 4. Breast cell-specific, hypoxia-mediated induction of EGFP expression in
stably transduced human cell lines. Selected, stably transduced populations of
four different breast cancer and five non-breast cancer cell lines (see legend
Fig. 3) were cultured for 96 h in an oxygen reduced atmosphere to induce
hypoxic conditions. Subsequently the cells were analysed by FACS and
compared to cells cultured under normoxic conditions. (A) Cells stably infected
with PCE-EpoE9W; (B) cells stably infected with PCEW. The relative increase
of expression levels in PCE-EpoE9W-infected cells compared to PCEW-
infected cells under normoxic and hypoxic conditions is illustrated in (C).
126 K. Lipnik et al. / Virology 349 (2006) 121–133was hardly detectable whereas tumours originating from PCE-
EpoE9W-infected cells showed a marked expression of the
transduced gene (Fig. 7, lower right panel).
Discussion
Current approaches in treatment of solid tumours usually
combine chemotherapy and radiotherapy. Hypoxia, a special
feature of solid tumours, adversely affects therapeutic efficacy
and may increase the risk for development of metastases and
tumour recurrence (Brizel et al., 1996; Dales et al., 2005; Fyles
et al., 2002; Hockel et al., 1996; To et al., 2005)). In the present
study, we established a retroviral vector-based gene delivery
system which exploits this specific tumour microenvironment
thereby facilitating a targeted and efficient transgene expression
in mammary tumour cells in vitro and in vivo.HREs derived from the erythropoietin encoding gene have
been previously shown to confer hypoxia inducibility to
ubiquitously active viral core promoters such as CMV and
SV40 (Greco et al., 2002; Wang et al., 2005). In addition, CArG
elements (Datta et al., 1992) fused to a minimal CMV promoter
also allowed induction of gene expression in response to gamma
irradiation (Scott and Marples, 2004; Scott et al., 2000). These
hybrid promoters have been used to drive expression of suicide
genes for application in cancer gene therapy approaches (Brown
andWilson, 2004; Greco et al., 2002; Scott and Greco, 2004). A
major prerequisite for gene therapy with viral vectors, however,
is a targeted delivery of the therapeutic gene. Therefore, in the
present approach synthetic hypoxia- and radiation-inducible
elements were coupled to a minimal fragment of the mammary-
specific murine WAP promoter (Lipnik et al., 2005; Öztürk-
Winder et al., 2002). The hybrid WAP promoter was then
introduced into a MLV-based retroviral promoter conversion
vector, a vector system which allows tissue-specific expression
of transferred genes in infected cells (Mrochen et al., 1997;
Saller et al., 1998). Detailed analysis of the generated vector in
vitro using three different stably transduced human breast
cancer cell lines revealed cell type-specific gradually different
responses to hypoxia with respect to reporter gene expression
levels (Table 1). This was already evident when the respective
elements fused to a minimal CMV promoter were analysed in
stably transfected cells (Fig. 1). Especially CoCl2-induced
transient hypoxia provoked an individual time-dependent
massive increase of EGFP expression levels ranging from 20-
fold to 60-fold, which might be due to the production of reactive
oxygen species during re-oxygenation followed by activation of
HIF-1 (Denko et al., 2003; Neubauer, 2001). Although overall
induction levels in stably infected cells were at least ten times
lower, a clear benefit of the hybrid promoter (PCE-EpoE9W) in
comparison to the basic WAP promoter (PCEW) was observed
under hypoxic conditions (Table 1). Interestingly, expression
levels of PCEW-infected cells chronically exposed to an oxygen
reduced atmosphere in all three cell lines decreased in
comparison to normoxic conditions, however, significant
changes were only obtained with cell populations. This effect
was not observed when cells were treated with fractionated
irradiation. In these experiments, also PCEW-infected cells
showed an increase of EGFP expression levels although to a
lesser extent compared to PCE-EpoE9W-infected cells.
Having shown that the modified WAP promoter can be
stimulated by hypoxia and radiation, the respective recombinant
vector virus was tested for tissue specificity by infection of a
number of breast cancer and non-breast cancer cell lines. In
transiently as well as in stably transduced cell lines (Figs. 3, 4)
cultivation under hypoxic conditions stimulated expression of
PCE-EpoE9W predominantly in infected breast cancer cells. An
increase above average was also obtained with microvascular
endothelial cells in both PCEW- and PCE-EpoE9W-infected
cells, when they were treated with 0.5 μM CoCl2 (Fig. 3A, B
hatched bars). This result therefore might indicate an overall
enhanced response of these cells to these distinct hypoxic
conditions rather than a specific effect on the introduced
enhancer elements (Roland et al., 2000).
Fig. 5. Immunohistochemical analysis of EGFP expression in mammary cancer cell xenografts. Consecutive sections of xenograft tumours derived fromMCF7 (A, B,
G, H) or MDA-MB534S cells (C–F) stably infected either with PCEW (A–D) or PCE-EpoE9W (E–H) were stained for detection of EGFP (A, C, E, G) or
pimonidazole-protein adducts (B, D, F, H) indicating hypoxic tumour areas. Circles indicate corresponding regions on consecutive sections. A blood vessel in sections
E and F is marked by an arrow. Photomicrographs were taken at a magnification of 200×.
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tem was recently described with an adenovirus-associated virus
vector system where a hypoxia-inducible, cardiac-specific
expression of VEGF was achieved by linking an HRE to the
myosin light chain promoter (Su et al., 2004). A retroviral
vector carrying an internal hypoxia-inducible hybrid promoter
consisting of the liver-specific α-fetoprotein (AFP) promoter
coupled to a VEGF promoter-derived HRE was shown to enable
a hepatoma cell-specific expression of therapeutically active
thymidine kinase (Ido et al., 2001). Using this approach, Ido and
co-workers managed to achieve a therapeutic effect even onxenograft tumours which were derived from low AFP-
expressing hepatoma cells.
A clear increase of promoter activity was demonstrated by
quantitative FACS analyses also in tumour tissue derived from
PCE-EpoE9W-infected T47D mammary cancer cells compared
to those infected with the vector PCEW bearing the basic WAP
promoter (Fig. 7). Detailed immunohistochemical and immu-
nofluorescence analyses strongly suggest that this increase in
expression levels is due to the enhancer elements linked to the
WAP promoter mediating expression within hypoxic and next
to necrotic tumour areas (Figs. 5 and 6). Recently, it was
Fig. 6. Immunofluorescence analysis of EGFP expression in mammary cancer cell xenografts. Sections of tumours derived fromMCF7 (A, B) or MDA-MB435 (C, D)
breast cancer cells stably transduced with PCEW (A, C) or PCE-EpoE9W (B, D) were simultaneously stained for detection of EGFP (green fluorescence) or
pimonidazole-protein adducts (Hypoxyprobe, red fluorescence). Colocalisation is indicated by an orange/yellow colour in merged pictures. Photomicrographs were
taken at a magnification of 400×.
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chemotherapeutic agents such as cisplatin (Park et al., 2002)
and cyclophosphamide (Dorie and Kallman, 1992) can enforce
tumour hypoxia. On the other hand, Greco et al. have shown
that besides irradiation also cisplatin and doxorubicin activate
promoters containing CArG elements (Greco et al., 2005).
Thus, in conclusion, data strongly recommend the respective
hypoxia and radiation responsive elements for an application in
expression targeted gene therapy delivery systems.
Materials and methods
Cell lines
Human mammary adenocarcinoma cells (MCF7; ATCC No:
HTB-22), were cultivated in Minimum Essential Medium withEarls Salts (MEM, Invitrogen Life Technologies) supplemented
with 10% foetal bovine serum (FBS; Invitrogen LT), 0.1 mM
non-essential amino acids (Invitrogen LT), 0.1 mM sodium
pyruvate (Invitrogen LT) and 1 mM bovine insulin (Sigma-
Aldrich). The human mammary carcinoma cell line T47D
(ATCC no: HTB-133) was grown in RPMI 1640 medium
(Invitrogen LT) supplemented with 10% FBS, 0.2 U/ml bovine
insulin, 2 mM L-glutamine (Invitrogen LT) and 1 mM sodium
pyruvate. The MDA-MB435S cell line (ATCC No: HTB-129),
derived from a pleural effusion metastasis of a human mammary
gland ductal carcinoma, was grown in Dulbecco's Minimum
Essential Medium (DMEM, Invitrogen LT) supplemented with
15% FBS. The human breast carcinoma cell line Hs578T
(ATCC No: HTB-126) was cultivated in DMEM supplemented
with 10% FBS and 0.01 mg/ml bovine insulin. The pancreatic
carcinoma cell line Panc1 (ATCC No: CRL-1469), the human
Fig. 7. Quantitative and qualitative analysis of EGFP expression in tumour xenografts derived from PCEW- or PCE-EpoE9W-transduced T47D cells. Parts of excised
tumours were either digested with collagenase to obtain single cell suspensions and analysed by FACS (left panels) or embedded in paraffin for immunohistochemical
detection of EGFP (right panels). The percentage of green fluorescent cells (area R3) contained in the amount of analysed cells is indicated. Representative data of one
tumour out of six are shown. Photomicrographs were taken at a magnification of 200×.
129K. Lipnik et al. / Virology 349 (2006) 121–133embryonic kidney cell line HEK293 (ATCC No: CRL-1573)
and the cervix carcinoma cell line HeLa (ATCC No: CCL-2)
were cultured in DMEM supplemented with 10% FBS. The
human microvascular endothelial cell line HMEC (Cambrex,
Verviers, Belgium) was maintained in EGMmedium (Cambrex)
and primary normal human dermal fibroblasts (huFi; NHDF-c;
PromoCell, Vienna, Austria;) were cultured in Amniomax C100
BASIC medium (Invitrogen, LT) supplemented with Amnio-
max C100 SUP (Invitrogen, LT). HEK293 derived amphotropic
retroviral packaging cells 2GP19Talf (Pambalk et al., 2002),
which stably provide the murine leukaemia virus (MLV) Env,
Gag and Pol proteins, were grown in DMEM supplemented
with 10% FBS. All cells were maintained at 37 °C in a
humidified atmosphere with 5% CO2.
Plasmids and retroviral vectors
The expression plasmid pEpoE9GFP (Fig. 2A) is described
elsewhere (Greco et al., 2002). The MLV-based retroviral
ProCon vector pPCEW (Fig. 2B) is a modification of the vector
pPCEMa published previously (Hlavaty et al., 2004). The U3
region of mouse mammary tumour virus (MMTV) located in
the 3′ LTR of pPCEMa was replaced by a 470-bp fragment of
the murine WAP promoter (Lipnik et al., 2005) giving rise to
pPCEW. For generation of pPCE-EpoE9-W (Fig. 2C) the Epo/E9 enhancer elements from pEpoE9GFP were amplified by
PCR using the oligonucleotide primers pEpoE9-for (5′-
GATACACCGCGGGATCTGGCCCTACGTGCT-3′) and
pEpoE9-rev (5′-GATACA CCGCGGATCGCCCAAA-
TAAGGCCAA-3′). Both primers contain a SacII restriction
endonuclease binding site (underlined) to facilitate cloning.
PCR was performed with 30 ng of pEpoE9GFP using Taq DNA
Polymerase (Promega) for 30 cycles (1 min 94 °C, 30 s 70 °C, 1
min 74 °C). A 270 bp Epo/E9-specific fragment was isolated
and introduced into a pCR-XL-TOPO PCR cloning vector
(Invitrogen, LT) followed by DNA sequencing. The Epo/E9
element was then isolated from pCR-XL-TOPO by restriction
digest with SacII and inserted into the SacII linearized vector
pPCEW 5′ of the WAP promoter. The resulting vector pPCE-
EpoE9W was finally sequenced with a primer binding within
the WAP promoter sequence (WAP rev: 5′-AAGAGGCTG
GCACAGCTCTA-3′).
Transfection and flow cytometric analysis
MCF7, T47D, MDA-MB435 and 2GP19Talf cells were
transfected following a calcium phosphate co-precipitation
protocol (Invitrogen LT). 5 μg of plasmid DNA were used per
well of a 6-well-plate. Stable populations and single cell clones
of transfected cells were selected by supplementing the
130 K. Lipnik et al. / Virology 349 (2006) 121–133respective culture medium with 400 μg/ml Geneticin (G418
sulfate, Invitrogen LT). For fluorescence-activated cell sorting
(FACS), cells were harvested and washed twice with
phosphate buffered saline (PBS, pH 7.4, AppliChem, Bio-
Chemica, Austria). Xenografts were digested to a single cell
suspension by incubation in collagenase dissolved in PBS
(Sigma; 5 mg/ml PBS) for 2 h at 37 °C with continuous mixing
and shaking. After 2 h digested tissue was supplemented with
DMEM/10% FCS and cells were harvested and washed as
described above. Finally cell pellets were resuspended in 1 ml
PBS and the cell suspension was filtered through gauze
(Bückmann, Germany). Fluorescence analysis for detection of
EGFP expression was performed using a FACScalibur (Becton
Dickinson) at an excitation wave length of 488 nm (Becton
Dickinson BP 530/30) and the CellQuest analysis software
(Becton Dickinson).
Retroviral infection
Retrovirus producing cells were obtained by G418
selection of 2GP19Talf packaging cells transfected with the
respective retroviral vector plasmids. Target cells were seeded
the day before infection at a density of 4 to 6 × 105 cells per
well of a 6-well-plate. Virus producing cells were seeded at
4 × 106 cells per well of a 6-well plate 2 days before the
infection experiment. The next day, their culture medium was
replaced by 2 ml of fresh DMEM/10% FBS. Twenty-four
hours later, virus containing cell culture supernatant was
filtered through a 0.45-μm filter (Sarstedt) and 1 ml, 100 μl or
10 μl thereof were used for infection of target cells in a total
volume of 1 ml DMEM/10% FBS. The cells were incubated
with recombinant virus for 6 h in the presence of 8 μg/ml
polybrene (Sigma-Aldrich). Thereafter, medium was replaced
with the respective cell type-specific culture medium. Cells
were harvested 72 h after infection and analysed by FACS for
determination of the number of infected cells. The viral titre
(green fluorescent units (gfu)/ml) was estimated according to
the percentage of EGFP positive cells. For generation of stably
transduced cell clones and populations, infected cells were
cultured in the presence of G418 (400 μg/ml) as described
above.
Generation of hypoxic conditions
For generation of hypoxic conditions two different methods
were applied. Cells were either seeded in duplicates in 6-well-
plates and kept in a hypoxic chamber which was inflated for 10
min with 10% CO2 compensated with nitrogen (Linde Gas,
H2O b5 ppm, O2 b3 ppm), or seeded in T25 flasks (Greiner) and
cultured in the presence of cobalt (II) chloride (99.9% metal
basis, Alfa Aesar, Johnson Matthey, Merck). For simulation of
transient hypoxia 4 μM (MDA-MB435S) and 2 μM (T47D,
MCF7) CoCl2 were applied. Chronic hypoxia was simulated by
incubating the cells in the presence of 0.1 μM (T47D), 0.3 μM
(MCF7) and 0.5 μM (MDA-MB435S) CoCl2 for up to 96 h. All
experiments were performed three times and the mean values
including standard deviations are depicted in the respectivefigures and tables. Significance of the obtained values
(P b 0.05) was calculated applying an unpaired t test (Graph
PadPrism 3.0).
X-ray exposure
For irradiation of cells, 8 × 105 MCF7 and T47D, and
4 × 105 MDA-MB435S cells respectively were seeded in 6 cm
Ø dishes. The day after seeding the culture medium was reduced
to 1 ml, the cover was removed and the cells were irradiated
with different doses of X-rays. The X-ray generator used
(Dermaopan, Siemens, Austria) contained a 0.3-mm aluminium
filter and was set to level 2 (29 kV) and 25 mA. The focus skin
distance was 10 cm. The irradiation time varied according to the
demanded dose which was determined using a gamma
dosimeter (X-ray-gamma-dosimeter 27060; Kuhm Analytik,
Klosterneuburg, Austria). Irradiation was applied for 24 s to
achieve a dose of 2.6 Gy. After irradiation, 50 μg/ml
gentamycin (Invitrogen, LT) was added to the culture medium.
Cells were harvested and analysed 48 h after irradiation. All
experiments were performed three times and the mean values
including standard deviations are depicted in the respective
figures and tables.
Viral RNA extraction and real time RT-PCR
For isolation of viral genomic RNA from particles, cell
culture supernatant of virus producing cells was digested with
1.9 U benzonase (Merck) at 37 °C for 1 h to remove interfering
cellular nucleic acids. Thereafter viral RNAwas extracted from
140 μl supernatant using the QIAamp viral RNA mini kit
(Qiagen). The amount of viral RNAwas determined by EGFP-
specific Taqman real-time RT-PCR. The sequences for
oligonucleotide primers and the fluorogenic probe as well as
the respective PCR conditions have been published previously
(Klein et al., 2000). The detected fluorescence signals were
analysed by using sequence detection software (SDS version
1.9.1; Applied Biosystems). The amount of viral RNA per 5 μl
sample was calculated by using a serial dilution of either in vitro
transcribed RNA or viral RNA as a standard. The reaction
efficiency of each assay was calculated by the method described
previously (Klein et al., 2001) and revealed only minimal
differences (b5%).
Establishment of tumour cell xenografts
MCF7, T47D and MDA-MB435S single cell clones and
populations, stably infected with PCE-EpoE9W or PCEW,
respectively, were cultured to 90% confluency in T175
flasks. 5 × 106 (MCF7, MDA-MB435) or 1 × 107 (T47D)
were mixed 1:1 (vol/vol) with matrigel (Becton Dickinson)
and injected subcutaneously into the pectoral mammary fat
pad of female SCID/beige mice (C.B-17/IcrHsd-Prkcdscid
Lystbg; Harlan-Winkelmann, Bochen, Germany). Additional-
ly, an estrogen pellet (1.7 mg, 21-day release, Innovative
Research of America, Sarasota) was implanted subcutane-
ously in the flank of those mice which were injected with
131K. Lipnik et al. / Virology 349 (2006) 121–133MCF7 and T47D cells. Mice were kept in scantainers
(Scanbur, Karlslunde, Denmark) under specific pathogen-free
conditions. They had free access to standard diets
(Altromin-R+M-H-1324, autoclaved; Altromin, Lage, Ger-
many) and autoclaved tap water. Tumour sizes were
measured twice a week in two dimensions with a calliper
and the tumour volume was calculated according to the
formula [l × w × w/2]. Five weeks post-implantation the
mice were injected intraperitoneally with a single dose of
HypoxyprobeTM-1 (60 mg/kg, pimonidazole hydrochloride,
Chemicon) in order to visualize hypoxic tumour regions. 15
min later mice were sacrificed, xenografts were excised,
fixed in formalin and analysed for EGFP expression and the
presence of hypoxia by immunohistochemistry. These animal
experiments were performed according to Austrian laws
governing animal experimentation (GZ) BMBWK-68.205/
0011-BrGT/2005.
Immunohistochemistry
Tumours were excised from the mammary fat pad, fixed in
4% buffered formaldehyde (pH 7.0) for 4–6 h at room
temperature, and embedded in Histo-Comp (Vogel, Giessen,
Germany) using an automatic embedding equipment (Tissue
Tek VIP 2000; Miles Scientific Inc., Mishawaka, IN, USA). 5
μm-thick sections were prepared and mounted on glass slides
pre-treated with poly-L-lysine (Sigma). Sections were de-
paraffinized in xylene and re-hydrated in a descending series
of ethanol (100%, 96%, and 70%). Deparaffinized sections
were pre-treated with 3% hydrogen peroxide in methanol for
15 min to inactivate endogenous peroxidase and rinsed in tap
water. After that, slides were put into an immunostaining
center (Sequenza, Shandon Scientific, Schwerte, Germany).
For detection of EGFP, slides were incubated with 1.5%
normal goat serum (DakoCytomation) for 30 min at room
temperature followed by an overnight incubation with the
primary antibody at 4 °C (rabbit anti-Aequorea victoria green
fluorescent protein, Molecular Probes, Invitrogen, LT; 1:4000
in PBS). Slides were then washed in PBS and incubated with
the peroxidase conjugated secondary antibody (anti-rabbit
EnVision+ TM, DakoCytomation) for 30 min at room
temperature. Subsequently, the sections were washed in PBS
and slides developed for 10 min at room temperature in 0.1%
3,3′-diaminobenzidine (DAB) hydrochloride containing 0.03%
hydrogen peroxide. The reaction was stopped by incubation in
distilled water for 5 min. Finally, sections were counterstained
with Mayer's hemalumn, dehydrated and mounted in DPX
mounting medium (Fluka). For detection of pimonidazole-
protein adducts, antigen retrieval was performed by incubating
the slides with 0.1% protease (Sigma) at room temperature for
10 min. Sections were then washed with PBS for 10 min and
incubated with 1% BSA in PBS (Sigma) for 5 min at room
temperature to minimize unspecific background staining. The
primary antibody incubation (mouse-anti pimonidazole,
Hypoxyprobe-1 MAb1, Chemicon, Hampshire, UK; 1:100 in
PBS) was performed at room temperature for 40 min. After
washing in PBS the secondary antibody (anti-mouse LabVi-sion+ TM, Labvision, Vienna, Austria) was applied for 30 min
at room temperature. Subsequent steps were performed as
described for EGFP staining. For the double fluorescence
staining slides were incubated with 1.5% normal goat serum
(DakoCytomation) for 30 min at room temperature followed
by an overnight incubation with the primary antibody at 4 °C
(rabbit anti-Aequorea victoria green fluorescent protein,
Molecular Probes, Invitrogen, LT; 1:2000 in PBS). After a
washing step with PBS for 5 min, a second protein block was
performed as described above. Then the slides were incubated
with the mouse-anti pimonidazole antibody (1:25 in PBS) for
2.5 h at room temperature and washed with PBS for 5 min.
Slides were then incubated with the secondary antibodies
Alexa Fluor goat anti-rabbit 488 (Vector laboratories, Vienna,
Austria; 1:100 in PBS) and Alexa Fluor goat anti-mouse 568
(Vector laboratories; 1:100 in PBS) for 1 h. Finally the slides
were washed with PBS for 5 min, with Aqua dest. for 2 min
and mounted with Mowiol (Fluka).
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